Author Correction: Genome-wide meta-analysis, fine-mapping and integrative prioritization implicate new Alzheimer's disease risk genes

Nat Genet. 2021 Apr;53(4):585-586. doi: 10.1038/s41588-021-00822-1.

Jeremy Schwartzentruber^{1

2

3}, Sarah Cooper^{4

5}, Jimmy Z Liu⁶, Inigo Barrio-Hernandez^{7

4}, Erica Bello^{4

5}, Natsuhiko Kumasaka⁵, Adam M H Young⁸, Robin J M Franklin⁸, Toby Johnson⁹, Karol Estrada¹⁰, Daniel J Gaffney^{4

5

11}, Pedro Beltrao^{7

4}, Andrew Bassett^{12

13}

¹ European Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Genome Campus, Cambridge, UK. jeremys@ebi.ac.uk.
² Open Targets, Wellcome Genome Campus, Cambridge, UK. jeremys@ebi.ac.uk.
³ Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, UK. jeremys@ebi.ac.uk.
⁴ Open Targets, Wellcome Genome Campus, Cambridge, UK.
⁵ Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, UK.
⁶ Biogen, Cambridge, MA, USA.
⁷ European Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Genome Campus, Cambridge, UK.
⁸ Wellcome-Medical Research Council Cambridge Stem Cell Institute, Cambridge Biomedical Campus, University of Cambridge, Cambridge, UK.
⁹ Target Sciences-R&D, GSK Medicines Research Centre, Stevenage, UK.
¹⁰ BioMarin Pharmaceutical, San Rafael, CA, USA.
¹¹ Genomics Plc, Oxford, UK.
¹² Open Targets, Wellcome Genome Campus, Cambridge, UK. ab42@sanger.ac.uk.
¹³ Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, UK. ab42@sanger.ac.uk.

No abstract available

Publication types